Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.

Morisaki, Takashi et al.·Anticancer research·2021·Preliminary Evidenceclinical trial
RPEP-05628Clinical trialPreliminary Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical trial
Evidence
Preliminary Evidence
Sample
N=17 patients
Participants
17 patients with treatment-resistant advanced solid tumors

What This Study Found

Intranodal neoantigen DC vaccination showed clinical responses in some advanced cancer patients, with response dependent on immune activation rather than neoantigen number.

Key Numbers

N=17; intranodal ultrasound-guided injection; ELISpot monitoring; response dependent on immune activation, not neoantigen number

How They Did This

Retrospective analysis of 17 patients with treatment-resistant advanced cancers. Whole exome sequencing for neoantigen prediction. Peptide-pulsed autologous DCs injected into lymph nodes via ultrasound. ELISpot immune monitoring.

Why This Research Matters

Personalized cancer vaccines could help patients who have run out of other options. Intranodal delivery may improve immune responses.

What This Study Doesn't Tell Us

Retrospective analysis. Small sample (N=17). No control group. Heterogeneous cancer types. Not all patients responded.

Trust & Context

Original Title:
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
Published In:
Anticancer research, 41(8), 4101-4115 (2021)
Database ID:
RPEP-05628

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-05628·https://rethinkpeptides.com/research/RPEP-05628

APA

Morisaki, Takashi; Morisaki, Takafumi; Kubo, Makoto; Onishi, Hideya; Hirano, Tatsuya; Morisaki, Shinji; Eto, Masatoshi; Monji, Keisuke; Takeuchi, Ario; Nakagawa, Shinichiro; Tanaka, Hiroto; Koya, Norihiro; Umebayashi, Masayo; Tsujimura, Kenta; Yew, Poh Yin; Yoshimura, Sachiko; Kiyotani, Kazuma; Nakamura, Yusuke. (2021). Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.. Anticancer research, 41(8), 4101-4115. https://doi.org/10.21873/anticanres.15213

MLA

Morisaki, Takashi, et al. "Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.." Anticancer research, 2021. https://doi.org/10.21873/anticanres.15213

RethinkPeptides

RethinkPeptides Research Database. "Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic C..." RPEP-05628. Retrieved from https://rethinkpeptides.com/research/morisaki-2021-efficacy-of-intranodal-neoantigen

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.